Los Angeles Capital Management LLC Decreases Stake in Humana Inc. (NYSE:HUM)

Los Angeles Capital Management LLC lowered its position in Humana Inc. (NYSE:HUM) by 97.6% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 604 shares of the insurance provider’s stock after selling 25,021 shares during the period. Los Angeles Capital Management LLC’s holdings in Humana were worth $226,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. CarsonAllaria Wealth Management Ltd. lifted its holdings in Humana by 111.4% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after purchasing an additional 39 shares in the last quarter. Hantz Financial Services Inc. purchased a new position in shares of Humana during the 2nd quarter worth $35,000. Family Firm Inc. purchased a new position in shares of Humana during the 2nd quarter worth $37,000. Riverview Trust Co purchased a new position in shares of Humana during the 2nd quarter worth $44,000. Finally, Carolinas Wealth Consulting LLC raised its holdings in shares of Humana by 274.1% during the 4th quarter. Carolinas Wealth Consulting LLC now owns 101 shares of the insurance provider’s stock worth $46,000 after acquiring an additional 74 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Price Performance

HUM stock opened at $321.56 on Monday. The business has a 50 day moving average price of $364.11 and a 200 day moving average price of $346.85. The stock has a market cap of $38.72 billion, a price-to-earnings ratio of 20.02, a PEG ratio of 2.56 and a beta of 0.50. Humana Inc. has a fifty-two week low of $298.61 and a fifty-two week high of $530.54. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.70.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. Humana had a return on equity of 16.12% and a net margin of 1.53%. The company had revenue of $29.54 billion during the quarter, compared to analysts’ expectations of $28.52 billion. During the same quarter in the previous year, the business earned $8.94 earnings per share. The firm’s revenue for the quarter was up 10.4% on a year-over-year basis. Equities research analysts anticipate that Humana Inc. will post 16 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Monday, September 30th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.10%. The ex-dividend date is Monday, September 30th. Humana’s dividend payout ratio is currently 22.04%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on HUM shares. Bank of America boosted their price objective on shares of Humana from $342.00 to $376.00 and gave the company a “neutral” rating in a report on Monday, May 20th. Robert W. Baird began coverage on shares of Humana in a report on Thursday, May 30th. They issued a “neutral” rating and a $374.00 price objective on the stock. Royal Bank of Canada lifted their target price on Humana from $385.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, September 5th. Oppenheimer lifted their target price on Humana from $370.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, August 1st. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $395.00 target price on shares of Humana in a research report on Tuesday, September 10th. Thirteen investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $398.70.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.